Scientists take a step towards better sleeping sickness treatment

(Medical Xpress) -- Scientists at the University of Glasgow have taken a major step forward in the quest to develop new, safer drugs for the treatment of sleeping sickness.

The team at the Wellcome Trust Centre for Molecular Parasitology has gained new insight into a specific within the parasite responsible for the disease, which could help in the design of new parasite-specific drugs.

Transmitted by the tsetse fly, is a neglected spread by the parasite. There are no effective vaccines for this disease and many of the drugs used to treat it are highly toxic. Left untreated it is invariably fatal.

Scientists believe that a better way of fighting the disease would be to target specific proteins in the parasite called metacaspases, which have been shown to be important for its .

A first step in creating such a is to understand the structure of the proteins and scientists at Glasgow have successfully determined the first three-dimensional structure of a metacapase – one of five found within T. brucei – using X-ray crystallography.

Dr Karen McLuskey, a senior research associate in the Wellcome Trust Centre for , said: “This structure allows us to visualise important details of how the metacaspase interacts with the proteins that it is destined to destroy”.

Professor Jeremy Mottram, leader of the research team, said “Overall, this structure provides a means towards designing specific inhibitors of metacaspases that can potentially be used for the development of novel drugs against parasitic diseases.”

The research, ‘Crystal structure of a Trypanosoma brucei metacaspase’, was funded by The Wellcome Trust and Medical Research Council and is published in the journal Proceedings of the National Academy of Sciences.

There are two forms of sleeping sickness (Human African Trypanosomiasis): Trypanosoma brucei gambiense, which accounts for 95 per cent of reported cases of sleeping sickness, and can infect a person for years without any major symptoms, often already having progressed to an advanced stage when signs do appear.

Trypanosoma brucei rhodesiense accounts for five percent of cases and progresses rapidly with symptoms apparent a few weeks or months after infection and quickly crossing the blood-brain barrier.

The disease progresses in two stages, the first characterised by fever, headaches, joint pain and itching, before progressing to the second phase when the invade the central nervous system. This stage results in reduced coordination, confusion, weakness, tremors and disruption of the sleep cycle resulting in insomnia and bouts of daytime sleeping from which the disease takes its name.

The World Health Organisation (WHO) reports that, after continued control efforts, the number of cases of HAT reported in 2009 has dropped below 10,000 for the first time in 50 years. The trend has been maintained in 2012 with 7,139 new cases reported. The estimated number of actual cases is 30,000.

Related Stories

Sleeping sickness finding could lead to earlier diagnosis

Apr 14, 2008

Sleeping sickness creates a metabolic 'fingerprint' in the blood and urine, which could enable a new test to be developed to diagnose the disease, according to new research published today in the journal Proceedings of th ...

Sequence is scaffold to study sleeping sickness

Apr 13, 2010

Researchers have made a further step toward understanding sleeping sickness - a chronic disease caused by Trypanosoma parasites, which affect the human central nervous system. The team have generated a high-quality draft ...

Fly gut bacteria could control sleeping sickness

May 11, 2010

A new bacterial species, found in the gut of the fly that transmits African sleeping sickness, could be engineered to kill the parasite that causes the disease. The study, published in the International Journal of Systematic an ...

Recommended for you

Increasing malarial drug resistance a growing threat

7 hours ago

(HealthDay)—The parasite that causes malaria is growing increasingly resistant to the drugs commonly used to fight it, according to new surveillance reports. But several new drugs are in development, and ...

User comments